Amedisys reported impressive second-quarter financial results with the top and the bottom line surpassing the respective Zacks Consensus Estimate and improving on a year-over-year basis as well. In Home Health, the company continued to generate strong organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative to drive organic growth as well as its search for strategically fit merger and acquisition activities. The company’s declaration about its ongoing restructuring program expected to be cost neutral, also raises investors’ optimism.
Currently, the stock carries a Zacks Rank #1 (Strong Buy). Some other well-placed medical stocks are AAC Holdings, Inc. AAC, Chemed Corp. CHE and DaVita HealthCare Partners Inc. DVA. While AAC holds the same Zacks Rank as Amedisys, the other two stocks carry a Zacks Rank #2 (Buy).